Anika Therapeutics Appoints Jing-wen Kuo as Chief Scientific Offices

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced the appointment of Jing-wen Kuo, Ph.D. as chief scientific officer. For the last nine years, Dr. Kuo has served in a variety of consulting capacities to many US and international clients specializing in hyaluronic acid based medical products.

Previously, from 1984 through 1998 Dr. Kuo was employed at Anika and his last position was that of vice president of technical and clinical development. As an integral member of the management team developing Anika's strategic growth plan, Dr. Kuo will lead the Company's overall research and development efforts as well as manage the Company's patent portfolio.